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Abstract
A distinct neurodevelopmental phenotype characterised mainly by mild motor and language delay and facial dysmorphism,
caused by heterozygous de novo or dominant variants in the TLK2 gene has recently been described. All cases reported
carried either truncating variants located throughout the gene, or missense changes principally located at the C-terminal end
of the protein mostly resulting in haploinsufficiency of TLK2. Through whole exome sequencing, we identified a
homozygous missense variant in TLK2 in a patient showing more severe symptoms than those previously described,
including cerebellar vermis hypoplasia and West syndrome. Both parents are heterozygous for the variant and clinically
unaffected highlighting that recessive variants in TLK2 can also be disease causing and may act through a different
pathomechanism.
Introduction
The TLK2 gene encodes the tousled-like kinase 2, a nuclear
serine/threonine kinase known to be involved in DNA
replication and chromatin assembly by phosphorylating
chromatin assembly factors, such as ASF1 and regulating
histone usage [1]. TLK2 was suggested as a candidate gene
for intellectual disability (ID) in a meta-analysis of de novo
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variants in 2104 exome trios [2], and recently Reijnders et al.
[3] associated it with ID within a broader phenotype in a
cohort of 40 individuals from 38 families. The cases presented
with a distinct neurodevelopmental phenotype characterised
by mild motor and language delay, behavioural problems,
facial dysmorphism and gastro-intestinal symptoms caused by
heterozygous de novo or dominant variants in TLK2. Trun-
cating (i.e. nonsense, frameshift and splice site) variants
located throughout the gene, or missense changes principally
located at the C-terminal end of the protein were identified
amongst the cohort. RNA analysis from patient derived cell
lines suggested that the variants resulted in loss-of-function
and that the most likely disease mechanism was hap-
loinsufficiency of TLK2. Here, we report a child carrying a
homozygous missense variant in TLK2 showing more severe
symptoms than those previously described.
Subject and methods
Patient and family members were recruited at the Department
of Paediatric Neurology, Izmir, Turkey. Written informed
consent was obtained. Whole exome sequencing (WES) was
performed by the Genomics Platform at the Broad Institute of
MIT and Harvard, Cambridge, USA. Libraries were created
with an Illumina exome capture (38Mb target) and sequenced
with a mean target coverage of >80 × . Exome sequencing
data were processed and analysed on the RD-Connect Gen-
ome-Phenome Analysis Platform (https://platform.rd-connect.
eu/genomics). Likely pathogenic variants, affecting the
function of the gene, and potentially causing disease, were
identified applying standard filtering criteria: minor allele
frequency <1%, and high to moderate variant effect predictor
(i.e. nonsense, splice site, frameshift, in-frame and non-
synonymous variants). Shortlisted variants were interrogated
for their predicted in silico deleteriousness and previous
known association with human disease. Genomic and phe-
notypic data have been submitted to RD-Connect under
accession numbers E287350, E180542 and E227711 (index
case, mother and father, respectively) where they can be
accessed under a controlled access agreement (https://pla
tform.rd-connect.eu/datasubmission/). Annotation of the
TLK2 gene is according to NM_006852.3.
Clinical description
The patient is a 6-year-old girl and the second child of
unaffected consanguineous parents of Turkish origin; her
9-year-old brother is healthy (Fig. 1). She was born at term
but had intrauterine growth retardation (birth weight 2400 g).
Intrauterine foetal movements were reduced and she had
hypotonia and hip dislocation at birth. She presented with
epileptic spasms at the age of 6 months. Her EEG showed
hypsarrhythmia suggesting West syndrome. She has been
seizure-free since 3 years of age. On clinical examination at 6
years of age her psychomotor and speech development were
severely delayed, she could sit without support but was
unable to walk or speak. She had microcephaly, coarse facial
appearance and dysmorphic facial features including
Fig. 1 Pedigree and Sanger
segregation of the TLK2 variant
(hg19 chr17:60599574 A>G).
The index case is homozygous
for the alternate allele (G/G),
whereas her unaffected brother
is homozygous wild type (A/A)
and his parents are heterozygous
(A/G) (indicated by an arrow).
No dysmorphic features are
observed in the healthy family
members, including those who
are carriers for the TLK2 variant
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telecanthus, upslanting palpebral fissures, thin vermilion
upper lip, big mouth and broad nasal bridge (Fig. 2a, b), and
a hemangioma on the left parietal scalp. In addition, she had
feeding difficulties, dysphagia, peripapillary atrophy on
fundoscopic examination and conductive hearing loss in the
left ear. Neurological examination detected spastic tetrapar-
esis with increased deep tendon reflexes, head titubation,
trunk ataxia and dysmetria. She also presented with con-
stipation and behavioural problems, including aggression and
irritability. Her brain MRI at age 2 years showed cerebellar
vermis hypoplasia (Dandy-Walker variant) and dilatation
of lateral ventricles (Fig. 2c, d). Abdominal MRI detected
medullary nephrocalcinosis and hydronephrosis.
Results
Trio analysis of the patient and her parents identified a
homozygous missense variant in the TLK2 gene (hg19
chr17: g.60599574 A>G; c.163 A>G; p.(Lys55Glu)), which
affects a highly conserved amino acid. The variant is pre-
dicted to be damaging by all tested in silico tools, is
amongst the top 0.2% most deleterious variants (CADD
score 27) [4] and is classified as ‘likely pathogenic’ by the
ACMG Guidelines [5]. This variant has been detected only
once, in a heterozygous European, out of 122,547 indivi-
duals in gnomAD and is absent from a cohort of 1182
ethnically-matched Turkish control individuals (TUBITAK
MAM-GMBE dataset; http://gmbe.mam.tubitak.gov.tr/en).
Sanger sequencing showed that the variant is not present in
her healthy brother, and that both parents are heterozygous
carriers. On examination they were clinically unaffected and
showed no signs of facial dysmorphism or cognitive
impairment (Fig. 1).
Discussion
We report a homozygous missense variant in TLK2 in a
patient with a neurodevelopmental disorder with severe
Fig. 2 Clinical findings.
a, b Patient photographs at
6 years of age showing facial
dysmorphism: telecanthus and
upslanting palpebral fissures,
thin vermilion upper lip, big
mouth and broad nasal bridge;
b Sagittal T2-weighted cranial
MR images showing cerebellar
vermis hypoplasia (Dandy-
Walker variant); c Axial T2-
weighted cranial MR images
showing cystic dilatation of the
cerebellum indicating cerebellar
vermis hypoplasia
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motor and language delay, West syndrome, pontocer-
ebellar hypoplasia, behavioural problems, facial dys-
morphism and gastro-intestinal symptoms. The clinical
presentation fits what has been described by Reijnders
et al. [3] for heterozygous TLK2 patients and the dys-
morphic features were remarkably similar. Our index
case, however, presented with more severe symptoms,
with profound ID, spastic tetraparesis and a structural
brain anomaly. Whilst conductive hearing loss, micro-
cephaly and non-specific brain anomalies were present in
a minority of reported cases (<25%), we are not aware of
cerebellar vermis hypoplasia, which we observed in the
homozygous individual. Although the majority of the
patients reported by Reijnders had language and cognitive
delay (92% and 74%, respectively), this was mainly mild
ID (IQ 50–70). In contrast, our patient presents severe
neurodevelopmental delay with no acquired speech
(although non-verbal IQ was not formally assessed).
Constipation and feeding difficulties were similar to other
individuals with heterozygous variants in TLK2. Medul-
lary nephrocalcinosis and hydronephrosis were not
observed in the previously published cohort.
All nine missense variants identified in the 38 families
described by Reijnders et al. [3] were located either in the
catalytic domain or in the coiled-coil motifs of the protein.
Our variant is located at the N -terminus in a region where
no functional domains are known (Fig. 3). This region,
however, is expected to contain a nuclear localisation
signal (NLS) as mutants lacking the first 160 amino acids
fail to localise to the nucleus [6]. In addition, more than
20 phosphorylation sites, including p.Thr52 and p.Tyr70,
have been identified in the N-terminal domain of TLK2,
suggesting that this is potentially an important regulatory
domain in vivo (https://www.phosphosite.org). In silico
tools (cNLS Mapper) predict a monopartite NLS
(61RNRKRKAEPY70) starting at position p.Arg61. NLSs
consist of stretches of basic amino acids, primarily lysine
and arginine, which bind to negative charges in the
binding grooves of the transport receptor. Amino acid
substitutions of lysine residues within NLSs can com-
pletely abolish their cargo nuclear import [7]. Although
speculative, it may be hypothesised that the change from a
positive (Lys) to a negative (Glu) side chain amino acid at
the proximal position p.Lys55 may result in a change in
conformation, partially occluding the binding between the
NLS-cargo and the import receptor. This would lead to
impaired nuclear import and in turn, diminished TLK2
activity.
In summary, here we describe a patient with a homo-
zygous TLK2 variant leading to an autosomal recessive
severe neurodevelopmental disorder, highlighting that cer-
tain TLK2 variants can cause a recessive disease, as the
heterozygous parents were healthy. The clinical presenta-
tion of our patient shows similarities with the previously
reported patients carrying heterozygous TLK2 variants,
however the symptoms are more severe and complicated
with additional features, such as cerebellar vermis hypo-
plasia and West syndrome. A reduction of available nuclear
TLK2 would be the proposed mechanism, although this
requires further functional investigation. We also highlight
the importance of searching not only for de novo and
dominant, but also recessive variants in TLK2 in patients
with neurodevelopmental disease. The identification of
additional cases will help to further delineate the recessive
TLK2 phenotype.
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Fig. 3 Schematic representation of the TLK2 missense variants identified. In black, the p.(Lys55Glu) reported here; in grey, the nine variants
previously reported by Reijnders et al. [3]. Annotation is according to NM_006852.3
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